Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A Virus-Like Particle Vaccine Elicits Broad Neutralizing Antibody Responses in Humans to All Chikungunya Virus Genotypes.

The Journal of infectious diseases - 15 Nov 2016

Goo Leslie, Dowd Kimberly A, Lin Tsai-Yu, Mascola John R, Graham Barney S, Ledgerwood Julie E, Pierson Theodore C

Abstract excerpt

Chikungunya virus (CHIKV) is an alphavirus that has emerged as a global health burden. There are 3 CHIKV genotypes: Asian, West African, and Eastern/Central/South African. No licensed CHIKV vaccine is available, and whether the antibody response elicited by one genotype can neutralize heterologous genotypes is unclear. We assessed neutralizing antibody (NAb) responses of volunteers in a phase 1 study of a CHIKV...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Neutralizing
Share to Antibodies, Viral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chikungunya Fever

Share to Chikungunya virus

Share to Cross Protection

Share to Cross Reactions

Share to Genotype

Share to Neutralization Tests

Source

Open in PubMed Open full text

Identifiers

PMID: 27655868
DOI: 10.1093/infdis/jiw431
PMCID: PMC5091377

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A Virus-Like Particle Vaccine Elicits Broad Neutralizing Antibody Responses in Humans to All Chikungunya Virus Genotypes.PMID 27655868Read ↗

Safety and immunogenicity of an adjuvanted chikungunya virus virus-like particle (CHIKV VLP) vaccine in previous recipients of other alphavirus vaccines versus alphavirus vaccine-naive controls: an open-label, parallel-group, age-matched, sex-matched, phase 2 randomised controlled studySemantic proximity Read ↗

Novel attenuated Chikungunya vaccine candidates elicit protective immunity in C57BL/6 mice.Semantic proximity Read ↗

The Safety and Efficacy of the Chikungunya Virus Vaccine: A Systematic Review and Meta Analysis.Semantic proximity Read ↗

Chikungunya virus vaccine: a decade of progress solving epidemiological dilemma, emerging concepts, and immunological interventionsSemantic proximity Read ↗

Safety and immunogenicity of a virus-like particle Chikungunya virus vaccineSemantic proximity Read ↗

Antigenic Variation of East/Central/South African and Asian Chikungunya Virus Genotypes in Neutralization by Immune Sera.Semantic proximity Read ↗

Antibody-based therapeutic interventions: possible strategy to counter chikungunya viral infection.Semantic proximity Read ↗

Attenuated and vectored vaccines protect nonhuman primates against Chikungunya virusSemantic proximity Read ↗

Chikungunya virus neutralization antigens and direct cell-to-cell transmission are revealed by human antibody-escape mutants.Semantic proximity Read ↗

Subunit vaccine formulations based on recombinant envelope proteins of Chikungunya virus elicit balanced Th1/Th2 response and virus-neutralizing antibodies in miceSemantic proximity Read ↗

Identification of immunogenic and cross-reactive chikungunya virus-specific CD4 <sup>+</sup> T cell epitopes in chronic chikungunya viral arthritic disease in humansSemantic proximity Read ↗

Antibody persistence and safety of a live-attenuated chikungunya virus vaccine up to 2 years after single-dose administration in adults in the USA: a single-arm, multicentre, phase 3b studySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.